Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.
Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- Check10 days agoChange DetectedAbbVie has added a new call center and updated details for a clinical trial in Essen, Germany, while the previous entry for ImmunoGen, Inc. has been removed.SummaryDifference2%
- Check31 days agoChange DetectedThe website has been updated to version v2.12.1, replacing the previous estimated update posted in version v2.12.0.SummaryDifference0.4%
- Check38 days agoChange DetectedThe website has added a new entry for Dr. Olivia Lara, MD, who is currently suspended, and updated to version v2.12.0, while removing the entry for Dr. Linda Van Le, MD, along with her contact information.SummaryDifference0.9%
- Check64 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.0%
- Check72 days agoChange DetectedA new study led by Dr. Jessica Parker in Dijon, France has been added, while the previous study by Dr. Olivia Lara has been removed along with a notice about delays in displaying study records.SummaryDifference0.7%
- Check79 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the site has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.3%
Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.